Esperoct

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Turoctocog Alfa pegol

Available from:

Novo Nordisk A/S

ATC code:

B02BD02

INN (International Name):

turoctocog alfa pegol

Therapeutic group:

Antihemorrhagics

Therapeutic area:

Hemofilija A

Therapeutic indications:

Prevencija i liječenje krvarenja kod bolesnika 12 godina s гемофилией a (urođeni deficit faktora VIII)u.

Product summary:

Revision: 6

Authorization status:

odobren

Authorization date:

2019-06-20

Patient Information leaflet

                                50
B. UPUTA O LIJEKU
51
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
ESPEROCT 500 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
ESPEROCT 1000 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
ESPEROCT 1500 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
ESPEROCT 2000 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
ESPEROCT 3000 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
ESPEROCT 4000 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
ESPEROCT 5000 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
turoktokog alfa pegol (pegilirani ljudski koagulacijski faktor VIII
(rDNA))
Ovaj je lijek pod dodatnim praćenjem. Time se omogućuje brzo
otkrivanje novih sigurnosnih
informacija. Prijavom svih sumnji na nuspojavu i Vi možete pomoći.
Za postupak prijavljivanja
nuspojava, pogledajte dio 4.
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE PRIMJENJIVATI
OVAJ LIJEK JER SADRŽI VAMA
VAŽNE PODATKE.
–
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
–
Ako imate dodatnih pitanja, obratite se liječniku.
–
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
–
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika. To uključuje i svaku
moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte dio 4.
ŠTO SE NALAZI U OVOJ UPUTI
1.
Što je Esperoct i za što se koristi
2.
Što morate znati prije nego počnete primjenjivati Esperoct
3.
Kako primjenjivati Esperoct
4.
Moguće nuspojave
5.
Kako čuvati Esperoct
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE ESPEROCT I ZA ŠTO SE KORISTI
ŠTO JE ESPEROCT
Esperoct sadrži djelatnu tvar turoktokog alfa pegol, a to je
dugodjelujući rekombinantni koagulacijski
faktor VIII. Faktor VIII je protein koji se nalazi u krvi, a pomaže
spriječiti i zaustaviti krvarenje.
ZA ŠTO SE ESPEROCT KORISTI
Esperoct se koristi za liječenje i sprječavanje krvarenja u osoba s
hemofilijom A (urođeni nedostatak
faktora VIII) u dobi od 12 i više godina.
U osoba s hemofilijom A faktor VI
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
Ovaj je lijek pod dodatnim praćenjem. Time se omogućuje brzo
otkrivanje novih sigurnosnih
informacija. Od zdravstvenih radnika se traži da prijave svaku sumnju
na nuspojavu za ovaj lijek. Za
postupak prijavljivanja nuspojava vidjeti dio 4.8.
1.
NAZIV LIJEKA
Esperoct 500 IU prašak i otapalo za otopinu za injekciju
Esperoct 1000 IU prašak i otapalo za otopinu za injekciju
Esperoct 1500 IU prašak i otapalo za otopinu za injekciju
Esperoct 2000 IU prašak i otapalo za otopinu za injekciju
Esperoct 3000 IU prašak i otapalo za otopinu za injekciju
Esperoct 4000 IU prašak i otapalo za otopinu za injekciju
Esperoct 5000 IU prašak i otapalo za otopinu za injekciju
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Esperoct 500 IU prašak i otapalo za otopinu za injekciju
Jedna bočica s praškom nominalno sadrži 500 IU turoktokog alfa
pegola*.
Nakon rekonstitucije, 1 ml otopine sadrži približno 125 IU
turoktokog alfa pegola.
Esperoct 1000 IU prašak i otapalo za otopinu za injekciju
Jedna bočica s praškom nominalno sadrži 1000 IU turoktokog alfa
pegola*.
Nakon rekonstitucije, 1 ml otopine sadrži približno 250 IU
turoktokog alfa pegola.
Esperoct 1500 IU prašak i otapalo za otopinu za injekciju
Jedna bočica s praškom nominalno sadrži 1500 IU turoktokog alfa
pegola*.
Nakon rekonstitucije, 1 ml otopine sadrži približno 375 IU
turoktokog alfa pegola.
Esperoct 2000 IU prašak i otapalo za otopinu za injekciju
Jedna bočica s praškom nominalno sadrži 2000 IU turoktokog alfa
pegola*.
Nakon rekonstitucije, 1 ml otopine sadrži približno 500 IU
turoktokog alfa pegola.
Esperoct 3000 IU prašak i otapalo za otopinu za injekciju
Jedna bočica s praškom nominalno sadrži 3000 IU turoktokog alfa
pegola*.
Nakon rekonstitucije, 1 ml otopine sadrži približno 750 IU
turoktokog alfa pegola.
Esperoct 4000 IU prašak i otapalo za otopinu za injekciju
Jedna bočica s praškom nominalno sadrži 4000 IU turoktokog alfa
pegola*.
Nakon rekonstitucije, 1 ml otopine sadrži približno 100
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 20-11-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 20-11-2023
Public Assessment Report Public Assessment Report Bulgarian 28-06-2019
Patient Information leaflet Patient Information leaflet Spanish 20-11-2023
Public Assessment Report Public Assessment Report Spanish 28-06-2019
Patient Information leaflet Patient Information leaflet Czech 20-11-2023
Public Assessment Report Public Assessment Report Czech 28-06-2019
Patient Information leaflet Patient Information leaflet Danish 20-11-2023
Public Assessment Report Public Assessment Report Danish 28-06-2019
Patient Information leaflet Patient Information leaflet German 20-11-2023
Public Assessment Report Public Assessment Report German 28-06-2019
Patient Information leaflet Patient Information leaflet Estonian 20-11-2023
Public Assessment Report Public Assessment Report Estonian 28-06-2019
Patient Information leaflet Patient Information leaflet Greek 20-11-2023
Public Assessment Report Public Assessment Report Greek 28-06-2019
Patient Information leaflet Patient Information leaflet English 20-11-2023
Public Assessment Report Public Assessment Report English 28-06-2019
Patient Information leaflet Patient Information leaflet French 20-11-2023
Public Assessment Report Public Assessment Report French 28-06-2019
Patient Information leaflet Patient Information leaflet Italian 20-11-2023
Public Assessment Report Public Assessment Report Italian 28-06-2019
Patient Information leaflet Patient Information leaflet Latvian 20-11-2023
Public Assessment Report Public Assessment Report Latvian 28-06-2019
Patient Information leaflet Patient Information leaflet Lithuanian 20-11-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 20-11-2023
Public Assessment Report Public Assessment Report Lithuanian 28-06-2019
Patient Information leaflet Patient Information leaflet Hungarian 20-11-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 20-11-2023
Public Assessment Report Public Assessment Report Hungarian 28-06-2019
Patient Information leaflet Patient Information leaflet Maltese 20-11-2023
Public Assessment Report Public Assessment Report Maltese 28-06-2019
Patient Information leaflet Patient Information leaflet Dutch 20-11-2023
Public Assessment Report Public Assessment Report Dutch 28-06-2019
Patient Information leaflet Patient Information leaflet Polish 20-11-2023
Public Assessment Report Public Assessment Report Polish 28-06-2019
Patient Information leaflet Patient Information leaflet Portuguese 20-11-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 20-11-2023
Public Assessment Report Public Assessment Report Portuguese 28-06-2019
Patient Information leaflet Patient Information leaflet Romanian 20-11-2023
Public Assessment Report Public Assessment Report Romanian 28-06-2019
Patient Information leaflet Patient Information leaflet Slovak 20-11-2023
Public Assessment Report Public Assessment Report Slovak 28-06-2019
Patient Information leaflet Patient Information leaflet Slovenian 20-11-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 20-11-2023
Public Assessment Report Public Assessment Report Slovenian 28-06-2019
Patient Information leaflet Patient Information leaflet Finnish 20-11-2023
Public Assessment Report Public Assessment Report Finnish 28-06-2019
Patient Information leaflet Patient Information leaflet Swedish 20-11-2023
Public Assessment Report Public Assessment Report Swedish 28-06-2019
Patient Information leaflet Patient Information leaflet Norwegian 20-11-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 20-11-2023
Patient Information leaflet Patient Information leaflet Icelandic 20-11-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 20-11-2023

Search alerts related to this product

View documents history